United Therapeutics (UTHR) – Investment Analysts’ Recent Ratings Updates

United Therapeutics (NASDAQ: UTHR) has recently received a number of price target changes and ratings updates:

  • 8/6/2019 – United Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/1/2019 – United Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/1/2019 – United Therapeutics was upgraded by analysts at Jefferies Financial Group Inc from an “underperform” rating to a “hold” rating. They now have a $90.00 price target on the stock.
  • 8/1/2019 – United Therapeutics had its “buy” rating reaffirmed by analysts at Wedbush. They now have a $273.00 price target on the stock.
  • 8/1/2019 – United Therapeutics was upgraded by analysts at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating. They now have a $106.00 price target on the stock, up previously from $103.00.
  • 7/31/2019 – United Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 7/16/2019 – United Therapeutics was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 7/2/2019 – United Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 7/1/2019 – United Therapeutics was upgraded by analysts at Credit Suisse Group AG from a “neutral” rating to an “outperform” rating. They now have a $101.00 price target on the stock, up previously from $98.00.
  • 6/11/2019 – United Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.

United Therapeutics stock traded up $1.51 during trading on Wednesday, hitting $79.89. The company’s stock had a trading volume of 368,198 shares, compared to its average volume of 562,471. The stock has a market capitalization of $3.44 billion, a PE ratio of 5.97 and a beta of 1.05. The stock has a fifty day moving average price of $78.32. United Therapeutics Co. has a 1-year low of $74.31 and a 1-year high of $130.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.62 and a quick ratio of 4.41.

In other United Therapeutics news, Director Raymond Dwek sold 3,750 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $76.11, for a total transaction of $285,412.50. Following the completion of the sale, the director now owns 3,750 shares of the company’s stock, valued at $285,412.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard Giltner sold 5,000 shares of the business’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $79.05, for a total value of $395,250.00. Following the sale, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $395,250. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of UTHR. Norges Bank purchased a new stake in United Therapeutics during the fourth quarter valued at about $54,233,000. Pictet Asset Management Ltd. boosted its position in shares of United Therapeutics by 64.0% in the first quarter. Pictet Asset Management Ltd. now owns 266,163 shares of the biotechnology company’s stock worth $31,240,000 after buying an additional 103,840 shares during the period. First Trust Advisors LP boosted its position in shares of United Therapeutics by 7.8% in the first quarter. First Trust Advisors LP now owns 1,290,590 shares of the biotechnology company’s stock worth $151,477,000 after buying an additional 93,786 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in shares of United Therapeutics by 26.0% in the first quarter. Robeco Institutional Asset Management B.V. now owns 402,159 shares of the biotechnology company’s stock worth $47,204,000 after buying an additional 83,037 shares during the period. Finally, Virginia Retirement Systems ET AL boosted its position in shares of United Therapeutics by 154.6% in the first quarter. Virginia Retirement Systems ET AL now owns 108,200 shares of the biotechnology company’s stock worth $12,699,000 after buying an additional 65,700 shares during the period. 94.81% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Story: SEC Filing

Receive News & Ratings for United Therapeutics Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co and related companies with MarketBeat.com's FREE daily email newsletter.